Screening for cervical cancer in HIV-infected womenAuthorWilliam R Robinson, MDSection EditorBarbara Goff, MDDeputy EditorSandy J Falk, MD, FACOG

Disclosures: William R Robinson, MD Nothing to disclose. Barbara Goff, MD Nothing to disclose. Sandy J Falk, MD, FACOG Nothing to disclose.

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

Conflict of interest policy

All topics are updated as new evidence becomes available and our peer review process is complete.Literature review current through: Jun 2015. | This topic last updated: Aug 19, 2014.

INTRODUCTION — The availability of cervical cytology to screen for cervical cancer often permits

diagnosis at the preinvasive stage, when treatment can almost always prevent progression to

invasive cancer. For this reason, screening for cervical cancer is important in all women. Screening

for cervical cancer is of particular concern to HIV-infected women and adolescents, since the

incidence of cervical intraepithelial neoplasia (CIN), as confirmed by colposcopy, is four to five times

higher in HIV-positive women and adolescents compared to HIV-negative women and adolescents

with high-risk sexual behaviors [1-3].

CIN is common in HIV-infected women because [4-8]:

●Both HIV and human papillomavirus (HPV) are sexually transmitted, and

●HIV-infected women are more likely to have persistent HPV infection, and

●Persistent infection with one or more oncogenic HPV subtypes is a major factor in the

pathogenesis of premalignant and malignant cervical disease

A study has reported that, unfortunately, as many as one-fourth of HIV-infected women do not get

an annual pap smear despite seeing a primary care provider during that time period, underscoring

the need for continued emphasis on cervical cancer screening in this population [9].

Specific issues regarding screening for cervical cancer in HIV-infected women will be reviewed

here. Evaluation and management of women with abnormal screening results and general issues

regarding screening for cervical cancer are discussed separately. (See "Preinvasive and invasive

cervical neoplasia in HIV-infected women"and "Cervical cancer screening tests: Techniques for

cervical cytology and human papillomavirus testing".)

CERVICAL CYTOLOGY — The performance of cervical cytology assessment alone as a screening

tool for cervical intraepithelial neoplasia (CIN)/cancer in women with HIV has been controversial,

with some studies reporting a low sensitivity for the detection of cytological abnormalities [10-13],

while other studies have been more reassuring about the reliability of this technique [1,14-18].

Either conventional Pap smears or liquid-based cervicovaginal preparations may be employed for

screening [19,20]. (See "Cervical cancer screening tests: Techniques for cervical cytology and

human papillomavirus testing".)

Cervical cytology appears to be reliable as a primary screening tool for cervical neoplasia:

●In one study, 391 HIV-seropositive and 103 seronegative women with atypical squamous

cells (ASC) or low-grade squamous intraepithelial lesions (LSIL) on cervical cytology and

negative colposcopy were followed for a mean of four years with cytology at six-month

intervals [21]. HIV-infected women had a slightly higher risk of progression than HIV-negative

women, but the absolute risk was low and did not justify further therapy.

●In another study, the HIV Epidemiology Research (HER) Study group followed 189 HIV-

infected women for six years [22]. Agreement between cytologic findings and colposcopic and

histologic findings was high, which led them to conclude that the routine use of colposcopy in

these individuals was not necessary.

●A multicenter study conducted in Europe and South Africa attempted to follow 1534 HIV-

positive women using cytology, HPV testing, and colposcopy (with histopathology when

indicated) at six-month intervals [17]. Median follow-up was about two years. Cytology

(≥ASCUS) and colposcopy had equivalent sensitivity for detecting women with CIN 2 or worse

(100 and 98 percent, respectively). HPV testing had similar sensitivity (91 percent), but was

much less specific (50 percent versus 65 percent for cytology and 63 percent for colposcopy).

Based on these findings, the authors concluded cytology was preferable to HPV testing or

colposcopy for screening HIV-positive women for cervical cancer.

Guidelines from the American College of Obstetricians and Gynecologists and the United States

Preventive Services Task Force recommend that women who are infected with HIV (or otherwise

immunocompromised) should undergo cervical cytology for cancer screening twice in the first year

after diagnosis of HIV infection and then annually, provided the test results are normal [23,24]. Two

cervical screening assessments initially is prudent for HIV-infected women, since intraepithelial

neoplasia is not uncommon and can develop rapidly in these women [2,25], and because high-

grade lesions may be missed with a single smear [13]. The efficacy of annual cervical cytology after

consistently negative results was illustrated in a study of 942 HIV-infected women [26]. After three

consecutive negative cytology results, after 15 months, there were no cases of precancer (CIN 2,3,

atypical glandular cells favor neoplasia, or adenocarcinoma in situ), and after 39 months, precancer

was found in 2 percent of women.

A cost-effectiveness analysis using a simulated clinical practice in the United States also supports

this recommendation [27]. This report compared six screening strategies in HIV-infected women: no

screening, annual Pap smear, annual Pap smear after two negative smears obtained six months

apart, semiannual Pap smears, annual colposcopy, and semiannual colposcopy. Annual Pap smear

after two negative smears obtained six months apart offered quality adjusted life expectancy

benefits at a cost comparable to other clinical preventive interventions. Semiannual Pap smear

screening provided additional quality adjusted life years (QALYs) but at significantly greater cost,

while colposcopy added significant cost but provided no further benefit.

Women with advanced HIV disease (particularly those controlled with highly active antiretroviral

therapy) appear to be more likely to have persistent HPV and CIN than those with early HIV

infections; however, there are no objective data showing that more aggressive screening is

indicated for these women or affects outcome.

It has been suggested that the use of highly active antiretroviral therapy (HAART) may reverse or

lessen the severity of cervical neoplasia in HIV-infected women, as is the case with other AIDS-

related malignancies [28-30]. However, multiple studies of this hypothesis have yielded mixed

results, and the incidence of invasive cervical neoplasia appears to be unchanged in the HAART

era [31-33].

Follow-up of normal results — For women with two consecutive normal cytological examinations,

we recommend that annual follow-up include a thorough visual inspection of the anus, vulva, and

vagina, as well as the cervix [34,35].

Evaluation of abnormal results — The American Society for Colposcopy and Cervical Pathology

2006 consensus guidelines advise that immunosuppressed women, including women who are HIV

positive, with atypical squamous cells of undetermined significance (ASC-US) may be managed the

same as women in the general population [36,37]. Women in this population do not appear to be at

increased risk of CIN 2,3 or HPV positivity [38,39]. Other cytologic abnormalities in women infected

with HIV should also be evaluated in the same manner as in other women. (See "Cervical cytology:

Evaluation of atypical squamous cells (ASC-US and ASC-H)", section on 'Immunocompromised

women'.)

Although rates of cytologic glandular abnormalities appear to increase with degree of

immunosuppression in HIV-positive women, glandular neoplasia is rare. This was illustrated in a

large cohort study that included almost 50,000 Pap tests [40]. Rates of glandular abnormalities on

cervical cytology did not differ significantly in HIV-positive (0.8 percent) compared with HIV-negative

women (0.6 percent). Among HIV-positive women, on the other hand, the rate of cytologic glandular

abnormalities increased significantly with decreasing CD4 lymphocyte count (>500/mm3: 0.6

percent; 250 to 500/mm3: 0.8 percent; <250/mm3: 1.0 percent). Ultimately, cervical biopsy found

only one HIV-positive woman with cervical adenocarcinoma and one HIV-negative woman with

glandular atypia; other women had negative histology or squamous abnormalities and showed no

significant difference by HIV serostatus.

Screening after hysterectomy — There is little information about the prevalence of vaginal

intraepithelial neoplasia in HIV-infected women who have undergone hysterectomy and how best to

follow these women. Uninfected women with no history of CIN who undergo hysterectomy for

benign disease have a near zero risk of developing vaginal intraepithelial neoplasia, so periodic

vaginal cytological screening is not recommended. Uninfected women with a history of CIN who

undergo hysterectomy for CIN or other benign disease have about a 1 percent risk of developing

vaginal intraepithelial neoplasia [41,42]; therefore, periodic cytology has been advised for these

women until three consecutive negative results have been obtained subsequent to the diagnosis of

CIN. (See "Screening for cervical cancer".)

By comparison, a study of 102 HIV-infected women who underwent hysterectomy for a variety of

indications reported 16 developed vaginal intraepithelial neoplasia within the first few years after

their surgery [43]. Nineteen of these women were known to have CIN or cervical cancer at the time

of hysterectomy, seven were known not to have any CIN, and there was no information on the other

76 patients. Of note, the seven women without CIN had normal vaginal cytology during median

follow-up of three years. Although the number of patients in this series is small and data are

incomplete, the high rate of vaginal intraepithelial neoplasia suggests that annual vaginal cytology

screening in HIV-infected women is a reasonable approach.

HUMAN PAPILLOMAVIRUS TESTING — A cost-effectiveness study evaluated the role of human

papillomavirus (HPV) testing for cervical cancer screening in HIV-infected women [44]. For HIV-

infected women on antiretroviral therapy, adding HPV testing to the two cervical cytology smears

obtained in the first year and then modifying subsequent screening based upon these results

(cervical cytology screening every six months for women with detectable HPV DNA and annual

screening for all others) was more effective and cost effective than annual screening alone.

Others have also found a low risk of cytological abnormalities in immunocompromised women who

test negative for high-risk subtypes of HPV and have normal CD4 counts. A cohort study showed

that HIV-infected women (mean age 37 years) with CD4 counts over 500/mcL, normal cervical

cytology, and HPV-negative test results at baseline were at low risk of developing cervical

intraepithelial neoplasia (CIN) in the next three years, and their risk was equivalent to that of HIV-

negative women [20].

On the other hand, a study of 103 women who were HIV positive and had CD4 counts less than 500

reported that the presence of a high-risk HPV subtype, although strongly associated with the

presence of any CIN, only slightly improved the sensitivity and predictive value of baseline

screening when compared to cytologic screening alone [15]. The lack of substantial benefit was

most likely due to the high prevalence of HPV infection in HIV-infected women. It appears that HIV-

infected women are more likely than other women to be infected with high-risk HPV subtypes other

than 16 and 18 and are likely to have persistent infection [45,46].

We feel the use of HPV testing to determine the frequency of subsequent screening in HIV-infected

women is a reasonable approach; women who test negative for HPV and have two negative initial

cervical cytology results could undergo cytological screening yearly (as discussed above), while

those with high-risk HPV DNA would have cervical cytology every six months. This is different from

the recommendation for HIV-negative women in whom prolongation of the screening interval to not

less than three years is recommended if both cytology and HPV results are normal. (See "Cervical

cancer screening tests: Techniques for cervical cytology and human papillomavirus testing", section

on 'HPV testing'.)

The US Food and Drug Administration (FDA) approved the cobas HPV test for use in co-testing or

as a standalone method of screening for women over age 24. This was based on a study of over

40,000 women, which showed that the test was safe and effective for the new indication for use

[47]. However, this study included no known HIV-infected subjects. As discussed above, historical

cervical screening techniques may be less effective in HIV-infected women. We therefore cannot

currently endorse the use of the cobas HPV test as a standalone screening technique for this

population. Additional large clinical trials are needed to determine whether subgroups of HIV-

positive women, such as those who are HPV negative and/or have normal CD4 counts, can be

screened for cervical cancer at screening intervals longer than one year. In the meantime, annual

screening with more frequent evaluation of those with abnormal cytology or high-risk HPV types is

recommended.

COLPOSCOPY — Many clinicians perform routine colposcopy in HIV-infected women, either with

the initial cervical cytology or annually. The rationale for this approach is:

●These women are usually seen in the health care system more often than once a year for

other reasons, so they would not require an additional visit (with its associated costs and

inconvenience) just for screening.

●The rate of noncompliance is high, thus, the potential need for a return visit for colposcopy is

eliminated.

●A higher rate of concurrent vulvar, vaginal, and anal neoplasias occurs in this group [34,35].

●Even mildly abnormal smears are associated with a high rate of histologic CIN (38 percent in

one series) [14].

Colposcopic examination of the vagina and vulva, as well as the cervix, should be included in the

evaluation because of the higher risk of multifocal disease [34,35]. (See"Colposcopy".)

We recommend a screening colposcopy at initial evaluation. We base the need for subsequent

examinations on cervical cytology results. (See 'Evaluation of abnormal results' above.).

SUMMARY AND RECOMMENDATIONS

●Women who are infected with HIV (or otherwise immunocompromised) should undergo

cervical cancer screening twice in the first year after diagnosis of HIV infection and then

annually, provided the test results are normal. (See 'Cervical cytology' above.)

●For women with two consecutive normal cytological examinations, we recommend that

annual follow-up include a thorough visual inspection of the anus, vulva, and vagina, as well

as the cervix. (See 'Follow-up of normal results' above.)

●There is no consensus as to whether human papillomavirus (HPV) testing should be

performed routinely on HIV-infected women. We suggest the use of HPV testing to determine

the frequency of subsequent cervical cancer screening in these women; women who test

negative for HPV and have two negative initial cervical cytology results could undergo

cytological screening yearly, while those with high-risk HPV DNA should have cervical

cytology every six months. (See'Human papillomavirus testing' above.)

●We recommend a screening colposcopy at initial evaluation. The need for subsequent

examinations is based upon cervical cytology results. (See 'Colposcopy'above.)Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

1. Wright TC Jr, Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84:591.

2. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031.

3. Moscicki AB, Ellenberg JH, Crowley-Nowick P, et al. Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 2004; 190:1413.

4. Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst 2005; 97:577.

5. Clifford GM, Gonçalves MA, Franceschi S, HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006; 20:2337.

6. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500.

7. Dal Maso L, Franceschi S, Polesel J, et al. Risk of cancer in persons with AIDS in Italy, 1985-1998. Br J Cancer 2003; 89:94.

8. Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 2006; 118:985.

9. Oster AM, Sullivan PS, Blair JM. Prevalence of cervical cancer screening of HIV-infected women in the United States. J Acquir Immune Defic Syndr 2009; 51:430.

10. Robinson WR, Barnes SE, Adams S, Perrin MS. Histology/cytology discrepancies in HIV-infected obstetric patients with normal pap smears. Gynecol Oncol 1997; 65:430.

11. Olaitan A, Mocroft A, McCarthy K, et al. Cervical abnormality and sexually transmitted disease screening in human immunodeficiency virus-positive women. Obstet Gynecol 1997; 89:71.

12. Maiman M, Fruchter RG, Sedlis A, et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecol Oncol 1998; 68:233.

13. Robinson WR, Luck MB, Kendall MA, Darragh TM. The predictive value of cytologic testing in women with the human immunodeficiency virus who have low-grade squamous cervical lesions: a substudy of a randomized, phase III chemoprevention trial. Am J Obstet Gynecol 2003; 188:896.

14. Wright TC Jr, Moscarelli RD, Dole P, et al. Significance of mild cytologic atypia in women infected with human immunodeficiency virus. Obstet Gynecol 1996; 87:515.

15. Cohn JA, Gagnon S, Spence MR, et al. The role of human papillomavirus deoxyribonucleic acid assay and repeated cervical cytologic examination in the detection of cervical intraepithelial neoplasia among human immunodeficiency virus-infected women. Cervical Disease Study Group of the American Foundation for AIDS Research Community Based Clinical Trials Network. Am J Obstet Gynecol 2001; 184:322.

16. Boardman LA, Peipert JF, Cooper AS, et al. Cytologic-histologic discrepancy in human immunodeficiency virus-positive women referred to a colposcopy clinic. Obstet Gynecol 1994; 84:1016.

17. Kitchener H, Nelson L, Adams J, et al. Colposcopy is not necessary to assess the risk to the cervix in HIV-positive women: an international cohort study of cervical pathology in HIV-1 positive women. Int J Cancer 2007; 121:2484.

18. Boardman LA, Cotter K, Raker C, Cu-Uvin S. Cervical intraepithelial neoplasia grade 2 or worse in human immunodeficiency virus-infected women with mildly abnormal cervical cytology. Obstet Gynecol 2008; 112:238.

19. Swierczynski SL, Lewis-Chambers S, Anderson JR, et al. Impact of liquid-based gynecologic cytology on an HIV-positive population. Acta Cytol 2004; 48:165.

20. Harris TG, Burk RD, Palefsky JM, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts, and human papillomavirus test results. JAMA 2005; 293:1471.

21. Massad LS, Evans CT, Strickler HD, et al. Outcome after negative colposcopy among human immunodeficiency virus-infected women with borderline cytologic abnormalities. Obstet Gynecol 2005; 106:525.

22. Anderson JR, Paramsothy P, Heilig C, et al. Accuracy of Papanicolaou test among HIV-infected women. Clin Infect Dis 2006; 42:562.

23. ACOG Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin No. 117: Gynecologic care for women with human immunodeficiency virus. Obstet Gynecol 2010; 116:1492.

24. United States Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd, Williams and Wilkins, Baltimore Vol 1996, p.105.

25. Holcomb K, Maiman M, Dimaio T, Gates J. Rapid progression to invasive cervix cancer in a woman infected with the human immunodeficiency virus. Obstet Gynecol 1998; 91:848.

26. Massad LS, DʼSouza G, Tian F, et al. Negative predictive value of pap testing: implications for screening intervals for women with human immunodeficiency virus. Obstet Gynecol 2012; 120:791.

27. Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits, and cost- effectiveness of screening for cervical cancer in HIV-infected women. Ann Intern Med 1999; 130:97.

28. Robinson WR, Freeman D. Improved outcome of cervical neoplasia in HIV-infected women in the era of highly active antiretroviral therapy. AIDS Patient Care STDS 2002; 16:61.

29. Robinson WR, Hamilton CA, Michaels SH, Kissinger P. Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol 2001; 184:538.

30. Soncini E, Zoncada A, Condemi V, et al. Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. Acta Biomed 2007; 78:36.

31. Heard I, Palefsky JM, Kazatchkine MD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 2004; 9:13.

32. Ahdieh-Grant L, Li R, Levine AM, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004; 96:1070.

33. Biggar RJ, Chaturvedi AK, Goedert JJ, et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 2007; 99:962.

34. Palefsky JM. Human papillomavirus-associated anogenital neoplasia and other solid tumors in human immunodeficiency virus-infected individuals. Curr Opin Oncol 1991; 3:881.

35. Abercrombie PD, Korn AP. Lower genital tract neoplasia in women with HIV infection. Oncology (Williston Park) 1998; 12:1735.

36. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013; 121:829.

37. www.ASCCP.org (Accessed on December 22, 2010).38. Massad LS, Schneider MF, Watts DH, et al. HPV testing for triage of HIV-infected women with

papanicolaou smears read as atypical squamous cells of uncertain significance. J Womens Health (Larchmt) 2004; 13:147.

39. Kirby TO, Allen ME, Alvarez RD, et al. High-risk human papillomavirus and cervical intraepithelial neoplasia at time of atypical squamous cells of undetermined significance cytologic results in a population with human immunodeficiency virus. J Low Genit Tract Dis 2004; 8:298.

40. Massad LS, Xie X, Darragh TM, et al. Histologic correlates of glandular abnormalities in cervical cytology among women with human immunodeficiency virus. Obstet Gynecol 2009; 114:1063.

41. Gemmell J, Holmes DM, Duncan ID. How frequently need vaginal smears be taken after hysterectomy for cervical intraepithelial neoplasia? Br J Obstet Gynaecol 1990; 97:58.

42. Wiener JJ, Sweetnam PM, Jones JM. Long term follow up of women after hysterectomy with a history of pre-invasive cancer of the cervix. Br J Obstet Gynaecol 1992; 99:907.

43. Paramsothy P, Duerr A, Heilig CM, et al. Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. J Acquir Immune Defic Syndr 2004; 35:484.

44. Goldie SJ, Freedberg KA, Weinstein MC, et al. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med 2001; 111:140.

45. McKenzie ND, Kobetz EN, Hnatyszyn J, et al. Women with HIV are more commonly infected with non-16 and -18 high-risk HPV types. Gynecol Oncol 2010; 116:572.

46. Heard I, Cubie HA, Mesher D, et al. Characteristics of HPV infection over time in European women who are HIV-1 positive. BJOG 2013; 120:41.

47. Rao A, Sandri MT, Sideri M, et al. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study. J Clin Virol 2013; 58:161.

Topic 3220 Version 9.0http://www.uptodate.com/contents/screening-for-cervical-cancer-in-hiv-infected-women?source=search_result&search=vph&selectedTitle=25~150